CalciMedica, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $151K | ↓-29.4% | — | — | — |
| 2025-09-30 | $140K | ↓-35.8% | $-8M | ↓-38.9% | -4012.9% |
| 2025-06-30 | $220K | ↓-20.0% | $-6M | ↓-50.6% | -3009.5% |
| 2025-03-31 | $202K | ↓-34.2% | $-5M | ↓-3978.5% | -3216.3% |
| 2024-12-31 | $214K | — | — | — | — |
| 2024-09-30 | $218K | — | $-6M | ↓-21.6% | -2631.2% |
| 2024-06-30 | $275K | — | $-4M | ↑+37.3% | -2374.2% |
| 2024-03-31 | $307K | — | $130K | ↑+100.7% | -1878.5% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
CALC Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyCALC Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics